Idiopathic pulmonary fibrosis (IPF) is a progressive disorder characterized by inflammation, fibroblast proliferation, and accumulation of extracellular matrix proteins. Leukotrienes (LTs) are pro-inflammatory and pro-fibrogenic mediators derived from the 5-lipoxygenase (5-LO) pathway of arachidonic acid metabolism. They are thought to play a role in a number of disease processes, but have received relatively little attention in investigations into the pathogenesis of IPF. In this study, we measured the levels of immunoreactive LTs B(4) and C(4) in homogenates of lung tissue obtained from patients with newly diagnosed, untreated IPF, as compared to levels measured in homogenates of uninvolved nonfibrotic lung tissue from patients undergoing resectional surgery for bronchogenic carcinoma. Compared to homogenates on nonfibrotic control lung, homogenates from IPF patients contained 15-fold more LTB(4) and 5-fold more LTC(4). IPF homogenate levels of LTB(4) were significantly correlated with histologic indices of both inflammation (r=0.861) and fibrosis (r=0.926). Activation of 5-LO is known from in vitro studies to be associated with localization of the enzyme at the nuclear membrane. Immunohistochemical staining for 5-LO protein in alveolar macrophages (AMs) demonstrated that such an "activated" localization pattern was significantly more frequent in IPF lung (19.2+/-3.3% of cells) than in control lung (9.3+/-0.9%); this localization pattern was rarely seen (3.2%) in sections from a truly normal transplant donor lung. Consistent with these data, AMs obtained from IPF patients by bronchoalveolar lavage, purified by adherence, and cultured in the absence of a stimulus for 16 h elaborated significantly greater amounts of LTB(4) and LTC(4) than did control AMs obtained from normal volunteers. These data indicate that the 5-LO pathway is constitutively activated in the lungs of patients with IPF, and the AM represents at least one cellular source of LT overproduction in this disorder. We speculate that LTs participate in the pathogenesis of IPF, and their overproduction in this disorder may be amenable to specific pharmacotherapy.
J Wilborn, M Bailie, M Coffey, M Burdick, R Strieter, M Peters-Golden
Title and authors | Publication | Year |
---|---|---|
Lipid metabolism in idiopathic pulmonary fibrosis: From pathogenesis to therapy.
Chen R, Dai J |
Journal of Molecular Medicine | 2023 |
The Dynamic Contribution of Neutrophils in the Chronic Respiratory Diseases
Ham J, Kim J, Ko YG, Kim HY |
Allergy, asthma & immunology research | 2022 |
Prospective phase II trial of montelukast to treat bronchiolitis obliterans syndrome after hematopoietic cell transplant and investigation into BOS pathogenesis
Williams KM, Pavletic SZ, Lee SJ, Martin PJ, Farthing DE, Hakim FT, Rose J, Manning-Geist BL, Gea-Banacloche JC, Comis LE, Cowen EW, Justus DG, Baird K, Cheng GS, Avila D, Steinberg SM, Mitchell SA, Gress RE |
2022 | |
Blocking 5-LO pathway alleviates renal fibrosis by inhibiting the epithelial-mesenchymal transition
J Zhou, R Li, Q Liu, J Zhang, H Huang, C Huang, G Zhang, Y Zhao, T Wu, Q Tang, Y Huang, Z Zhang, Y Li, J He |
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie | 2021 |
Chondroitin sulfate in tissue remodeling: Therapeutic implications for pulmonary fibrosis
Y Kai, H Yoneyama, M Yoshikawa, H Kimura, S Muro |
Respiratory Investigation | 2021 |
The role of lipid-based signalling in wound healing and senescence
V Pils, L Terlecki-Zaniewicz, M Schosserer, J Grillari, I Lämmermann |
Mechanisms of Ageing and Development | 2021 |
Design and synthesis of Leukotriene A4 hydrolase inhibitors to alleviate idiopathic pulmonary fibrosis and acute lung injury
X Li, M Xie, C Lu, J Mao, Y Cao, Y Yang, Y Wei, X Liu, S Cao, Y Song, J Peng, Y Zhou, Q Jiang, G Lin, S Qin, M Qi, M Hou, X Liu, H Zhou, G Yang, C Yang |
European Journal of Medicinal Chemistry | 2020 |
Lipid Mediators Regulate Pulmonary Fibrosis: Potential Mechanisms and Signaling Pathways
V Suryadevara, R Ramchandran, DW Kamp, V Natarajan |
International journal of molecular sciences | 2020 |
The role of the LTB4-BLT1 axis in health and disease
R He, Chen, Q Cai |
Pharmacological research : the official journal of the Italian Pharmacological Society | 2020 |
Phosphorylation of 5-LOX: The Potential Set-point of Inflammation
Z He, D Tao, J Xiong, F Lou, J Zhang, J Chen, W Dai, J Sun, Y Wang |
Neurochemical Research | 2020 |
Exercise Improves Lung Inflammation, but Not Lung Remodeling and Mechanics in a Model of Bleomycin-Induced Lung Fibrosis
E El-Mafarjeh, GH Martins, JJ Probst, A Santos-Dias, MC Oliveira-Junior, MP de Barros, LV de Oliveira, LD de Andrade, RK da Palma, R Moraes-Ferreira, D de Camargo Hizume-Kunzler, AL Bachi, RP Vieira, G gory Durand |
Oxidative Medicine & Cellular Longevity | 2020 |
Tannic acid alleviates experimental pulmonary fibrosis in mice by inhibiting inflammatory response and fibrotic process
N Rajasekar, A Sivanantham, A Kar, SK Mahapatra, R Ahirwar, RK Thimmulappa, SG Paramasivam, R Subbiah |
Inflammopharmacology | 2020 |
Secretion of leukotrienes by senescent lung fibroblasts promotes pulmonary fibrosis
Christopher D Wiley, Alexis Brumwell, Sonnet S Davis, Julia Jackson, Alexis Valdovinos, Cheresa Calhoun, Fatouma Alimirah, Carlos A. Castellanos, Richard Ruan, Ying Wei, Harold Chapman, Arvind Ramanathan, Judith Campisi, Claude Jourdan Le Saux |
JCI Insight | 2019 |
Targeting metabolic dysregulation for fibrosis therapy
X Zhao, JY Kwan, K Yip, PP Liu, FF Liu |
Nature Reviews Drug Discovery | 2019 |
Role of the high-affinity leukotriene B4 receptor signaling in fibrosis after unilateral ureteral obstruction in mice
M Kamata, H Amano, Y Ito, T Fujita, F Otaka, K Hosono, K Kamata, Y Takeuchi, T Yokomizo, T Shimizu, M Majima, JC Dussaule |
PloS one | 2019 |
Lipids - two sides of the same coin in lung fibrosis
A Mamazhakypov, RT Schermuly, L Schaefer, M Wygrecka |
Cellular Signalling | 2019 |
Novel drug targets in idiopathic pulmonary fibrosis
M Calvello, MC Flore, L Richeldi |
Expert Opinion on Orphan Drugs | 2019 |
Eicosanoids in carcinogenesis
BL Brücher, IS Jamall, OR Bandapalli |
2019 | |
AK106-001616, a Potent and Selective Inhibitor of Cytosolic Phospholipase A 2 : In Vivo Efficacy for Inflammation, Neuropathic Pain, and Pulmonary Fibrosis
H Shimizu, A Ito, K Sakurada, J Nakamura, K Tanaka, M Komatsu, M Takeda, K Saito, Y Endo, T Kozaki, M Shoda, H Kuriyama |
The Journal of pharmacology and experimental therapeutics | 2019 |
Therapeutic targets and early stage clinical trials for pulmonary fibrosis
S Sato, T Yanagihara, MR Kolb |
Expert Opinion on Investigational Drugs | 2018 |
An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis
S Aryal, SD Nathan |
Expert Opinion on Emerging Drugs | 2018 |
Approved and Experimental Therapies for Idiopathic Pulmonary Fibrosis
G Pasciuto, R Inchingolo, C Condoluci, D Magnini, B Iovene, L Richeldi |
Current Pulmonology Reports | 2018 |
Idiopathic Pulmonary Fibrosis: A Comprehensive Clinical Guide
KC Meyer, SD Nathan |
2018 | |
Tepoxalin a dual 5-LOX-COX inhibitor and erlotinib an EGFR inhibitor halts progression of gastric cancer in tumor xenograft mice
Xinyang Lu, Lunhua Huang, Wei Zhang, Xiaofei Ning |
American journal of translational research | 2018 |
Protective effect of cysteinyl leukotriene receptor antagonist montelukast in bleomycin-induced pulmonary fibrosis
N Topaloğlu |
Turkish Journal of Thoracic and Cardiovascular Surgery | 2018 |
Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis
W Lu, X Yao, P Ouyang, N Dong, D Wu, X Jiang, Z Wu, C Zhang, Z Xu, Y Tang, S Zou, M Liu, J Li, M Zeng, P Lin, F Cheng, J Huang |
Journal of Medicinal Chemistry | 2017 |
Drug repurposing in idiopathic pulmonary fibrosis filtered by a bioinformatics-derived composite score
E Karatzas, MM Bourdakou, G Kolios, GM Spyrou |
Scientific Reports | 2017 |
New treatment directions for IPF: current status of ongoing and upcoming clinical trials
F Macagno, F Varone, PM Leone, PV Mari, L Panico, L Berardini, L Richeldi |
Expert Review of Respiratory Medicine | 2017 |
Investigational drugs for idiopathic pulmonary fibrosis
F Varone, G Montemurro, F Macagno, M Calvello, E Conte, E Intini, B Iovene, PM Leone, PV Mari, L Richeldi |
Expert Opinion on Investigational Drugs | 2017 |
Are newly launched pharmacotherapies efficacious in treating idiopathic pulmonary fibrosis? Or is there still more work to be done?
R Inchingolo, C Condoluci, A Smargiassi, A Mastrobattista, C Boccabella, A Comes, N Golfi, L Richeldi |
Expert Opinion on Pharmacotherapy | 2017 |
Therapeutic targets in idiopathic pulmonary fibrosis
M Kolb, F Bonella, L Wollin |
Respiratory Medicine | 2017 |
BLT1 Mediates Bleomycin-Induced Lung Fibrosis Independently of Neutrophils and CD4 + T Cells
J Lv, Y Xiong, W Li, W Yang, L Zhao, R He |
Journal of immunology (Baltimore, Md. : 1950) | 2017 |
Leukotrienes in exhaled breath condensate and fractional exhaled nitric oxide in workers exposed to TiO 2 nanoparticles
D Pelclova, V Zdimal, P Kacer, Z Fenclova, S Vlckova, M Komarc, T Navratil, J Schwarz, N Zikova, O Makes, K Syslova, J Belacek, S Zakharov |
Journal of Breath Research | 2016 |
Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation
KM Williams, GS Cheng, I Pusic, M Jagasia, L Burns, VT Ho, J Pidala, J Palmer, L Johnston, S Mayer, JW Chien, DA Jacobsohn, SZ Pavletic, PJ Martin, BE Storer, Y Inamoto, X Chai, ME Flowers, SJ Lee |
Biology of Blood and Marrow Transplantation | 2016 |
How I treat bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation
KM Williams |
Blood | 2016 |
Paracrine functions of fibrocytes to promote lung fibrosis
KR Kleaveland, BB Moore, KK Kim |
Expert Review of Respiratory Medicine | 2014 |
Following the Path of CCL2 from Prostaglandins to Periostin in Lung Fibrosis
BB Moore |
American journal of respiratory cell and molecular biology | 2014 |
Emerging therapeutic interventions for idiopathic pulmonary fibrosis
S Chakraborty, P Chopra, SV Ambi, SG Dastidar, A Ray |
Expert Opinion on Investigational Drugs | 2014 |
Targeted therapies for systemic sclerosis
CP Denton, VH Ong |
Nature Reviews Rheumatology | 2013 |
Leukotriene C 4 aggravates bleomycin-induced pulmonary fibrosis in mice: LTC 4 aggravates pulmonary fibrosis
H Hirata, M Arima, Y Fukushima, K Sugiyama, T Tokuhisa, T Fukuda |
Respirology | 2013 |
5-Lipoxygenase mRNA and Protein Isoforms
MJ Ochs, B Suess, D Steinhilber |
Basic & Clinical Pharmacology & Toxicology | 2013 |
Discovery of a novel activator of 5-lipoxygenase from an anacardic acid derived compound collection
R Wisastra, PA Kok, N Eleftheriadis, MP Baumgartner, CJ Camacho, HJ Haisma, FJ Dekker |
Bioorganic & Medicinal Chemistry | 2013 |
Pranlukast, a Cysteinyl Leukotriene Type 1 Receptor Antagonist, Attenuates the Progression but Not the Onset of Silica-Induced Pulmonary Fibrosis in Mice
C Shimbori, N Shiota, H Okunishi |
International Archives of Allergy and Immunology | 2012 |
Modulatory Effects of Curcumin and Green Tea Extract against Experimentally Induced Pulmonary Fibrosis: A Comparison with N -Acetyl Cysteine: MODULATION OF PULMONARY FIBROSIS
MA Hamdy, SA El-Maraghy, MA el Kortam |
Journal of Biochemical and Molecular Toxicology | 2012 |
Leukotrienes B4, C4, D4 and E4 in the Exhaled Breath Condensate (EBC), Blood and Urine in Patients with Pneumoconiosis
D PELCLOV^|^Aacute;, Z FENCLOV^|^Aacute;, S VLCKOV^|^Aacute;, J LEBEDOV^|^Aacute;, K SYSLOV^|^Aacute;, O PECHA, J BEL^|^Aacute;CEK, T NAVR^|^Aacute;TIL, M KUZMA, P KACER |
Industrial Health | 2012 |
Prostaglandin E2 and the Pathogenesis of Pulmonary Fibrosis
PD Bozyk, BB Moore |
American journal of respiratory cell and molecular biology | 2011 |
Integrating mechanisms of pulmonary fibrosis
TA Wynn |
Journal of Experimental Medicine | 2011 |
Novel therapeutic approaches for pulmonary fibrosis
A Datta, CJ Scotton, RC Chambers |
British Journal of Pharmacology | 2011 |
Diagnosis and treatment of pulmonary chronic GVHD: report from the consensus conference on clinical practice in chronic GVHD
GC Hildebrandt, T Fazekas, A Lawitschka, H Bertz, H Greinix, J Halter, SZ Pavletic, E Holler, D Wolff |
Bone Marrow Transplantation | 2011 |
An Official American Thoracic Society Workshop Report: Features and Measurements of Experimental Acute Lung Injury in Animals
G Matute-Bello, G Downey, BB Moore, SD Groshong, MA Matthay, AS Slutsky, WM Kuebler |
American journal of respiratory cell and molecular biology | 2011 |
Preventing and managing bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplantation
JW Chien |
Expert Review of Respiratory Medicine | 2011 |
Effects of montelukast, a cysteinyl-leukotriene type 1 receptor antagonist, on the pathogenesis of bleomycin-induced pulmonary fibrosis in mice
C Shimbori, N Shiota, H Okunishi |
European Journal of Pharmacology | 2011 |
Investigational approaches to therapies for idiopathic pulmonary fibrosis
RH Gomer, ML Lupher |
Expert Opinion on Investigational Drugs | 2010 |
Viral infection and aging as cofactors for the development of pulmonary fibrosis
PK Naik, BB Moore |
Expert Review of Respiratory Medicine | 2010 |
Fluticasone, azithromycin and montelukast therapy in reducing corticosteroid exposure in bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: a case series of eight patients
BC Norman, DA Jacobsohn, KM Williams, BK Au, MA Au, SJ Lee, CK Moravec, JW Chien |
Bone Marrow Transplantation | 2010 |
Retinoic acids exhibit anti-fibrotic activity through the inhibition of 5-lipoxygenase expression in scleroderma fibroblasts
R XIAO, N YOSHIDA, Y HIGASHI, QJ LU, T FUKUSHIGE, T KANZAKI, T KANEKURA |
The Journal of Dermatology | 2010 |
Leukotriene B4, administered via intracerebroventricular injection, attenuates the antigen-induced asthmatic response in sensitized guinea pigs
YL Zhu, SJ Zhang, YM Deng, XW Dong, JX Jiang, QM Xie |
Journal of Neuroinflammation | 2010 |
Effect of inhaled KP-496, a novel dual antagonist of the cysteinyl leukotriene and thromboxane A2 receptors, on a bleomycin-induced pulmonary fibrosis model in mice
S Kurokawa, M Suda, T Okuda, Y Miyake, Y Matsumura, M Ishimura, R Saito, T Nakamura |
Pulmonary Pharmacology & Therapeutics | 2010 |
Splanchnic Hypoperfusion Provokes Acute Lung Injury via a 5-Lipoxygenase Dependent Mechanism
EE Moore |
The American Journal of Surgery | 2010 |
Involvement of leukotrienes in the pathogenesis of silica-induced pulmonary fibrosis in mice
C Shimbori, N Shiota, H Okunishi |
Experimental Lung Research | 2010 |
Pulmonary surfactant: an immunological perspective
ZC Chroneos, Z Sever-Chroneos, VL Shepherd |
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology | 2009 |
Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation - An Increasingly Recognized Manifestation of Chronic Graft-versus-Host Disease
JW Chien, S Duncan, KM Williams, SZ Pavletic |
Biology of Blood and Marrow Transplantation | 2009 |
Determinants of initiation and progression of idiopathic pulmonary fibrosis
RM KOTTMANN, CM HOGAN, RP PHIPPS, PJ SIME |
Respirology | 2009 |
Latent herpesvirus infection augments experimental pulmonary fibrosis
KM Vannella, TR Luckhardt, CA Wilke, LF van Dyk, GB Toews, BB Moore |
American journal of respiratory and critical care medicine | 2009 |
Bronchiolitis Obliterans After Allogeneic Hematopoietic Stem Cell Transplantation
KM Williams |
Journal of the American Medical Association | 2009 |
Inflammation and cancer: how friendly is the relationship for cancer patients?
BB Aggarwal, P Gehlot |
Current Opinion in Pharmacology | 2009 |
Viruses as co-factors for the initiation or exacerbation of lung fibrosis
KM Vannella, BB Moore |
Fibrogenesis & Tissue Repair | 2008 |
Eicosanoid Lipid Mediators in Fibrotic Lung Diseases
SK Huang, M Peters-Golden |
Chest | 2008 |
Mechanisms of Disease: leukotrienes and lipoxins in scleroderma lung disease—insights and potential therapeutic implications
O Kowal-Bielecka, K Kowal, O Distler, S Gay |
Nature Clinical Practice Rheumatology | 2007 |
Current and emerging drugs for idiopathic pulmonary fibrosis
M Gharaee-Kermani, B Hu, VJ Thannickal, SH Phan, MR Gyetko |
Expert Opinion on Emerging Drugs | 2007 |
Pharmacotherapy of diseases mediated by 5-lipoxygenase pathway eicosanoids
P Rubin, KW Mollison |
Prostaglandins & Other Lipid Mediators | 2007 |
Cysteinyl-leukotriene 1 receptor antagonist attenuates bleomycin-induced pulmonary fibrosis in mice
T Izumo, M Kondo, A Nagai |
Life Sciences | 2007 |
Cysteinyl Leukotrienes Are Autocrine and Paracrine Regulators of Fibrocyte Function1
KM Vannella, TR McMillan, RP Charbeneau, CA Wilke, PE Thomas, GB Toews, M Peters-Golden, BB Moore |
Journal of immunology (Baltimore, Md. : 1950) | 2007 |
The histone deacetylase inhibitor trichostatin A mediates upregulation of 5-lipoxygenase promoter activity by recruitment of Sp1 to distinct GC-boxes
N Schnur, S Seuter, C Katryniok, O Rådmark, D Steinhilber |
Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids | 2007 |
8-isoprostane and Leukotrienes in Exhaled Breath Condensate in Czech Subjects with Silicosis
D PELCLOVÁ, Z FENCLOVÁ, P KAČER, T NAVRÁTIL, M KUZMA, J LEBEDOVÁ, P KLUSÁČKOVÁ |
Industrial Health | 2007 |
Cysteinyl Leukotrienes Are Autocrine and Paracrine Regulators of Fibrocyte Function
KM Vannella, TR McMillan, RP Charbeneau, CA Wilke, PE Thomas, GB Toews, M Peters-Golden, BB Moore |
Journal of immunology (Baltimore, Md. : 1950) | 2007 |
Epithelial-mesenchymal interactions in pulmonary fibrosis
JC Horowitz, VJ Thannickal |
Seminars in respiratory and critical care medicine | 2006 |
Pharmacological inhibition of leukotrienes in an animal model of bleomycin-induced acute lung injury
M Failla, T Genovese, E Mazzon, E Gili, C Muià, M Sortino, N Crimi, AP Caputi, S Cuzzocrea, C Vancheri |
Respiratory Research | 2006 |
Idiopathic Pulmonary Fibrosis
JC Horowitz, VJ Thannickal |
Treatments in Respiratory Medicine | 2006 |
Opposing roles of leukotrienes and prostaglandins in fibrotic lung disease
BB Moore, M Peters-Golden |
Expert Review of Clinical Immunology | 2006 |
Expression of 5-lipoxygenase in specialized epithelial cells of nasopharyngeal-associated lymphoid tissue
TG Brock |
Journal Of Molecular Histology | 2006 |
Cysteinyl Leukotriene Levels in Esophageal Mucosal Biopsies of Children with Eosinophilic Inflammation: Are They All the Same?
SK Gupta, M Peters-Golden, JF Fitzgerald, JM Croffie, MD Pfefferkorn, JP Molleston, MR Corkins, JR Lim |
The American Journal of Gastroenterology | 2006 |
Idiopathic pulmonary fibrosis : new concepts in pathogenesis and implications for drug therapy
JC Horowitz, VJ Thannickal |
Treatments in Respiratory Medicine | 2006 |
Idiopathic Pulmonary Fibrosis: New Concepts in Pathogenesis and Implications for Drug Therapy
JC Horowitz, VJ Thannickal |
Treatments in Respiratory Medicine | 2006 |
Hepcidin expression and iron transport in alveolar macrophages
NB Nguyen, KD Callaghan, AJ Ghio, DJ Haile, F Yang |
American journal of physiology. Lung cellular and molecular physiology | 2006 |
Role of 5-Lipoxygenase in IL-13-Induced Pulmonary Inflammation and Remodeling
YM Shim, Z Zhu, T Zheng, CG Lee, RJ Homer, B Ma, JA Elias |
Journal of immunology (Baltimore, Md. : 1950) | 2006 |
TNF-alpha sensitizes normal and fibrotic human lung fibroblasts to Fas-induced apoptosis
SK Frankel, GP Cosgrove, SI Cha, CD Cool, MW Wynes, BL Edelman, KK Brown, DW Riches |
American journal of respiratory cell and molecular biology | 2005 |
Regulating leukotriene synthesis: The role of nuclear 5-lipoxygenase
TG Brock |
Journal of Cellular Biochemistry | 2005 |
Molecular mechanisms underlying inflammatory lung diseases in the elderly: Development of a novel therapeutic strategy for acute lung injury and pulmonary fibrosis
T Nagase, T Aoki-Nagase, Y Yamaguchi, H Yamamoto, Y Ouchi |
Geriatrics and Gerontology International | 2005 |
Cyclooxygenase- and lipoxygenase-derived eicosanoids in bronchoalveolar lavage fluid from patients with scleroderma lung disease: An imbalance between proinflammatory and antiinflammatory lipid mediators
O Kowal-Bielecka, K Kowal, O Distler, J Rojewska, A Bodzenta-Lukaszyk, BA Michel, RE Gay, S Gay, S Sierakowski |
Arthritis & Rheumatism | 2005 |
Emerging drugs for idiopathic pulmonary fibrosis
VJ Thannickal, KR Flaherty, RC Hyzy, JP 3rd |
Expert Opinion on Emerging Drugs | 2005 |
Traitements médicamenteux de la fibrose pulmonaire idiopathique
B Crestani, S Marchand-Adam, S Schneider |
Revue de Pneumologie Clinique | 2005 |
Group IB secretory phospholipase A2 stimulates leukotriene B4 production by a unique mechanism in human neutrophils
HY Lee, MK Kim, KS Park, EH Shin, YS Bae |
Biochemical and Biophysical Research Communications | 2005 |
Effects of montelukast treatment on clinical and inflammatory variables in patients with cystic fibrosis
I Stelmach, A Korzeniewska, W Stelmach, P Majak, T Grzelewski, J Jerzynska |
Annals of Allergy Asthma & Immunology | 2005 |
Fibrosis pulmonar idiopática: en busca de un tratamiento eficaz
M Selman, C Navarro, M Gaxiola |
Archivos de Bronconeumología | 2005 |
Involvement of cAMP-response element binding protein-1 in arachidonic acid-induced vascular smooth muscle cell motility
N Dronadula, F Rizvi, E Blaskova, Q Li, GN Rao |
Journal of lipid research | 2005 |
Nuclear localization of leukotriene A 4 hydrolase in type II alveolar epithelial cells in normal and fibrotic lung
TG Brock, YJ Lee, E Maydanski, TL Marburger, M Luo, R Paine, M Peters-Golden |
American journal of physiology. Lung cellular and molecular physiology | 2005 |
Phosphorylation by Protein Kinase A Inhibits Nuclear Import of 5-Lipoxygenase
M Luo, SM Jones, N Flamand, DM Aronoff, M Peters-Golden, TG Brock |
The Journal of biological chemistry | 2005 |
Toward functional proteomics of alveolar macrophages
HM Wu, M Jin, CB Marsh |
American journal of physiology. Lung cellular and molecular physiology | 2005 |
Cysteinyl leukotriene 1 receptor controls the severity of chronic pulmonary inflammation and fibrosis
TC Beller, DS Friend, A Maekawa, BK Lam, KF Austen, Y Kanaoka |
Proceedings of the National Academy of Sciences | 2004 |
Mechanisms of Pulmonary Fibrosis
VJ Thannickal, GB Toews, ES White, JP Lynch, FJ Martinez |
Annual Review of Medicine | 2004 |
Cysteinyl leukotrienes: biosynthesis and receptors
B Lam, Y Kanaoka, J Boyce, KF Austen |
Clinical & Experimental Allergy Reviews | 2004 |
Idiopathic pulmonary fibrosis: emerging concepts on pharmacotherapy
VJ Thannickal, KR Flaherty, FJ Martinez, JP 3rd |
Expert Opinion on Pharmacotherapy | 2004 |
Five-lipoxygenase-activating protein inhibitor MK-886 induces apoptosis in gastric cancer through upregulation of p27kip1and bax
XM Fan, SP Tu, SK Lam, WP Wang, J Wu, WM Wong, MF Yuen, MC Lin, HF Kung, BC Wong |
Journal of Gastroenterology and Hepatology | 2004 |
Montelukast and airway remodeling in children with chronic persistent asthma: an open study
M Pifferi, D Caramella, V Ragazzo, ED Marco, A Pietrobelli, AL Boner |
Pediatric Allergy and Immunology | 2004 |
Medical treatment for pulmonary fibrosis: current trends, concepts, and prospects
KK Brown, G Raghu |
Clinics in Chest Medicine | 2004 |
Characterization of Interleukin-4–Stimulated Nasal Polyp Fibroblasts
JW Steinke, CD Crouse, D Bradley, K Hise, K Lynch, SE Kountakis, L Borish |
American journal of respiratory cell and molecular biology | 2004 |
Idiopathic Pulmonary Fibrosis: Pathogenesis and Therapeutic Approaches
M Selman, VJ Thannickal, A Pardo, DA Zisman, FJ Martinez, JP Lynch |
Drugs | 2004 |
Effect of Montelukast, a Cysteinyl Receptor Antagonist, on Myofibroblasts in Interstitial Lung Disease
E Fireman, Y Schwartz, A Mann, J Greif |
Journal of Clinical Immunology | 2004 |
Disorders of lung matrix remodeling.
Chapman HA |
Journal of Clinical Investigation | 2004 |
NOVELPHARMACOLOGICALAPPROACHES TOMANAGEINTERSTITIALLUNGFIBROSIS IN THETWENTY-FIRSTCENTURY
SN Giri |
Annual Review of Pharmacology and Toxicology | 2003 |
Leukotriene C4 synthase
BK Lam |
Prostaglandins, Leukotrienes and Essential Fatty Acids | 2003 |
5-Lipoxygenase and FLAP
M Peters-Golden, TG Brock |
Prostaglandins, Leukotrienes and Essential Fatty Acids | 2003 |
The plasmin system in airway remodeling
I Kucharewicz, K Kowal, W Buczko, A Bodzenta-Łukaszyk |
Thrombosis Research | 2003 |
N OVEL P HARMACOLOGICAL A PPROACHES TO M ANAGE I NTERSTITIAL L UNG F IBROSIS IN THE T WENTY -F IRST C ENTURY
SN Giri |
Annual Review of Pharmacology and Toxicology | 2003 |
Lung Biology in Health and Disease
N Zamel |
Lung Biology in Health and Disease: Experimental Models and Therapeutic Potential | 2003 |
Lung Biology in Health and Disease: Potential Mediators and Therapeutic Targets in Fibrotic Lung Disease
M Peters-Golden |
Lung Biology in Health and Disease: Experimental Models and Therapeutic Potential | 2003 |
Roles of cysteinyl leukotrienes in airway inflammation, smooth muscle function, and remodeling
Stephen T Holgate, Marc Peters-Golden, Reynold A Panettieri, William R Henderson Jr |
Journal of Allergy and Clinical Immunology | 2003 |
Elevated levels of leukotriene B4 and leukotriene E4 in bronchoalveolar lavage fluid from patients with scleroderma lung disease
O Kowal-Bielecka, O Distler, K Kowal, Z Siergiejko, J Chwieko, A Sulik, RE Gay, AB ukaszyk, S Gay, S Sierakowski |
Arthritis & Rheumatism | 2003 |
Rheumatoid arthritis and leukotriene receptor
A Hashimoto, S Kono, H Endo, H Kondo |
Ensho Saisei | 2003 |
A Role for Cysteinyl Leukotrienes in Airway Remodeling in a Mouse Asthma Model
WR Henderson, LO Tang, SJ Chu, SM Tsao, GK Chiang, F Jones, M Jonas, C Pae, H Wang, EY Chi |
American journal of respiratory and critical care medicine | 2002 |
A pivotal role of cytosolic phospholipase A(2) in bleomycin-induced pulmonary fibrosis
T Nagase, N Uozumi, S Ishii, Y Kita, H Yamamoto, E Ohga, Y Ouchi, T Shimizu |
Nature Medicine | 2002 |
Future Research Directions in Idiopathic Pulmonary Fibrosis: Summary of a National Heart, Lung, and Blood Institute Working Group
RG Crystal, PB Bitterman, B Mossman, MI Schwarz, D Sheppard, L Almasy, HA Chapman, SL Friedman, TE King, LA Leinwand, L Liotta, GR Martin, DA Schwartz, GS Schultz, CR Wagner, RA Musson |
American journal of respiratory and critical care medicine | 2002 |
The 5-Lipoxygenase Pathway: A New Therapeutic Target for the Treatment of Pulmonary Fibrosis
DC Zeldin |
American journal of respiratory and critical care medicine | 2002 |
Protection from Pulmonary Fibrosis in Leukotriene-Deficient Mice
M Peters-Golden, M Bailie, T Marshall, C Wilke, SH Phan, GB Toews, BB Moore |
American journal of respiratory and critical care medicine | 2002 |
Oxidant-mediated increases in redox factor-1 nuclear protein and activator protein-1 DNA binding in asbestos-treated macrophages
DM Flaherty, MM Monick, AB Carter, MW Peterson, GW Hunninghake |
Journal of immunology (Baltimore, Md. : 1950) | 2002 |
Cyclooxygenase-2 deficiency results in a loss of the anti-proliferative response to transforming growth factor-beta in human fibrotic lung fibroblasts and promotes bleomycin-induced pulmonary fibrosis in mice
CB Keerthisingam, RG Jenkins, NK Harrison, NA Hernandez-Rodriguez, H Booth, GJ Laurent, SL Hart, ML Foster, RJ McAnulty |
The American Journal of Pathology | 2001 |
Potential role of leukotrienes in other disease states
M Peters-Golden |
Clinical & Experimental Allergy Reviews | 2001 |
Origins and treatment of airway inflammation in childhood asthma
RF Lemanske |
Pediatric Pulmonology | 2001 |
Inflammation
JA Hunt |
Encyclopedia of Materials Science and Technology | 2001 |
GM-CSF Increases AP-1 DNA Binding and Ref-1 Amounts in Human Alveolar Macrophages
DM Flaherty, MM Monick, AB Carter, MW Peterson, GW Hunninghake |
American journal of respiratory cell and molecular biology | 2001 |
Intracellular Compartmentalization of Leukotriene Biosynthesis
M Peters-Golden, TG Brock |
American journal of respiratory and critical care medicine | 2000 |
Differential expression of CC chemokines and the CCR5 receptor in the pancreas is associated with progression to type I diabetes
MJ Cameron, GA Arreaza, M Grattan, C Meagher, S Sharif, MD Burdick, RM Strieter, DN Cook, TL Delovitch |
Journal of immunology (Baltimore, Md. : 1950) | 2000 |
Prolonged Exposure to Lipopolysaccharide Inhibits Macrophage 5-Lipoxygenase Metabolism Via Induction of Nitric Oxide Synthesis
MJ Coffey, SM Phare, M Peters-Golden |
Journal of immunology (Baltimore, Md. : 1950) | 2000 |
In Situ Amplification of 5-Lipoxygenase and 5-Lipoxygenase-Activating Protein in Allergic Airway Inflammation and Inhibition by Leukotriene Blockade
SJ Chu, LO Tang, E Watney, EY Chi, WR Henderson |
Journal of immunology (Baltimore, Md. : 1950) | 2000 |
Pulmonary diseases other than asthma as potential targets for antileukotriene therapy
M Peters-Golden |
Clinical Reviews in Allergy & Immunology | 1999 |
The Biology of 5-Lipoxygenase: Function, Structure, and Regulatory Mechanisms
ES Silverman, JM Drazen |
Proceedings of The Association of American Physicians | 1999 |
Pharmacological Therapy for Idiopathic Pulmonary Fibrosis: Past, Present, and Future
RJ Mason, MI Schwarz, GW Hunninghake, RA Musson |
American journal of respiratory and critical care medicine | 1999 |
Immunoglobulins and Cellular Constituents of the BAL Fluid of Patients With Sulfur Mustard Gas-Induced Pulmonary Fibrosis
A Emad, GR Rezaian |
Chest | 1999 |
Novel Inhibitors of Leukotrienes
G Folco, B Samuelsson, RC Murphy |
1999 | |
Molecular mechanisms of leukotriene synthesis: the changing paradigm
Peters-Golden |
Clinical & Experimental Allergy | 1998 |
Collagenase-3 induction in rat lung fibroblasts requires the combined effects of tumor necrosis factor-alpha and 12-lipoxygenase metabolites: a model of macrophage-induced, fibroblast-driven extracellular matrix remodeling during inflammatory lung injury
TJ Mariani, S Sandefur, JD Roby, RA Pierce |
Molecular biology of the cell | 1998 |
Capacity for repeatable leukotriene generation after transient stimulation of mast cells and macrophages
TG Brock, RW McNish, M Peters-Golden |
Biochemical Journal | 1998 |
Role of leukotrienes in antimicrobial defense of the lung
M Peters-Golden, M Coffey |
Journal of Laboratory and Clinical Medicine | 1998 |
5-Lipoxygenase and 5-Lipoxygenase Activating Protein (FLAP) Immunoreactivity in Lungs from Patients with Primary Pulmonary Hypertension
L Wright, RM Tuder, J Wang, CD Cool, RA Lepley, NF Voelkel |
American journal of respiratory and critical care medicine | 1998 |
Cell Biology of the 5-Lipoxygenase Pathway
M Peters-Golden |
American journal of respiratory and critical care medicine | 1998 |
Altered expression and localization of 5-lipoxygenase accompany macrophage differentiation in the lung
RB Covin, TG Brock, MB Bailie, M Peters-Golden |
American journal of physiology. Lung cellular and molecular physiology | 1998 |
γ-linolenic acid-containing diet attenuates bleomycin-induced lung fibrosis in hamsters
VA Ziboh, M Yun, DM Hyde, SN Giri |
Lipids | 1997 |
Rapid Import of Cytosolic 5-Lipoxygenase into the Nucleus of Neutrophils after in Vivo Recruitment and in Vitro Adherence
TG Brock, RW McNish, MB Bailie, M Peters-Golden |
The Journal of biological chemistry | 1997 |
The molecular biology of mammalian lipoxygenases and the quest for eicosanoid functions using lipoxygenase-deficient mice
CD Funk |
Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism | 1996 |
Leukotrienes
J Ophir, S Brenner, S Kivity |
International Journal of Dermatology | 1985 |